Urinary Tract 10-208

January 03, 2017

Sponsor: Memorial Sloan Kettering Cancer Center

Number: 10-208
Some patients with bladder cancer have better outcomes if they receive chemotherapy before they undergo surgery. In this Phase III study, researchers want to see if this approach, called neoadjuvant chemotherapy, can lead to improved outcomes for patients.

Who’s eligible: Patients must have high-grade transitional cell carcinoma of the upper urinary tract (kidney/ureter) and be candidates for nephrectomy (kidney removal).

Patients may not have had prior radiation therapy or chemotherapy for their urothelial cancer.

Patients must be age 18 or older.

Available at: Hartford Hospital.